New publication from the MACUSTAR study!
We show that relative ellipsoid zone reflectivity (rEZR) on OCT is associated with the different metrics of retinal function in AMD —supporting rEZR as a structural biomarker of retinal integrity.
https://t.co/rwbkE1GQ0S
Ein neuer Meilenstein für MACUSTAR: Das Projekt hat von der Europäischen Arzneimittelagentur (EMA) ein drittes Unterstützungsschreiben erhalten! https://t.co/tmNR58TTY4
We are looking back to a successful MACUSTAR General Assembly meeting 2024 in Bonn:
Milestones, scientific output, and regulatory strategy were reviewed and discussed.
We engaged in many productive conversations about strategies for managing this remarkable project's future!
New MACUSTAR publication! 👁���"Generalizable Deep Learning for the Detection of Incomplete and Complete Retinal Pigment Epithelium and Outer Retinal Atrophy-A MACUSTAR report" Advancing AI-driven precision in retinal disease detection! Read more: https://t.co/OhGYi0SMy4
🎙️ New #EURETINA Podcast Ep 48: Assessing Visual Deficits in Intermediate AMD. Prof. Frank Holz & Dr. Hannah Dunbar dive into findings from the Macustar trial, offering insights into patient care and strategies.
🎧 Listen: https://t.co/nPAE1cbMID
#AMD#Macustar
Looking back to this year´s exciting 7th MACUSTAR General Assembly meeting in Bonn. Very fruiful discussions on 8 different presentations covering the different MACUSTAR workgroups- so much collaborative high quality work going on!
The EMA issued a second letter of support for MACUSTAR!
The letter of support is published on the MACUSTAR website under the following link:
https://t.co/KhvnU7jFa7
and on the EMA website:
https://t.co/NtkNJ842v6
Macular disease is the biggest cause of sight loss in the UK. It affects people of all ages. There is no cure but there are things you can do to look after your eyes. Our free eye health pack provides practical tips #EyeWeek#EyeHealth#VisionMatters https://t.co/bzkGzxPBn9